CTMX Q4 2020 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+97.8% YoY

Gross Profit

$16M100.0% margin

Operating Income

-$15M-90.3% margin

Net Income

-$15M-89.8% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-8.0%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$359M

Total Liabilities

$366M

Stockholders' Equity

-$8M

Cash & Equivalents

$192M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$8M	+97.8%
Gross Profit	$16M	$8M	+97.8%
Operating Income	-$15M	-$37M	+60.5%
Net Income	-$15M	-$35M	+58.5%